MeiraGTx Holdings Plc

As of October 10, 2025, MeiraGTx Holdings Plc shows a mildly bullish trend overall, despite mixed signals from various indicators, suggesting caution in investment decisions.

As of October 10, 2025, MeiraGTx Holdings Plc shows a mildly bullish trend with mixed indicators, including a mildly bearish weekly MACD and bullish monthly momentum, but lacks return data for comparison with the S&P 500.

As of October 10, 2025, MeiraGTx Holdings Plc shows a mildly bullish technical trend, supported by daily moving averages and Bollinger Bands, despite mixed signals from MACD and KST indicators, while year-to-date performance is strong at 28.74% compared to the S&P 500's 11.41%.

As of October 3, 2025, MeiraGTx Holdings Plc shows a bullish trend with strong MACD and moving average indicators, despite some caution from the KST and OBV, and has significantly outperformed the S&P 500 with a year-to-date return of 38.10% compared to 14.18%.

As of October 3, 2025, MeiraGTx Holdings Plc shows a bullish trend supported by daily moving averages and monthly indicators, despite some short-term caution from weekly metrics, with a strong recent performance of 15.28% over the past month and 106.10% over the past year.

As of October 3, 2025, MeiraGTx Holdings Plc shows a bullish technical trend, supported by strong daily moving averages and Bollinger Bands, despite mixed signals from the MACD and KST, and has outperformed the S&P 500 with a 106.10% return over the past year.

As of September 19, 2025, MeiraGTx Holdings Plc has a mildly bullish trend, supported by monthly bullish indicators and daily moving averages, while outperforming the S&P 500 in the short term but underperforming over the past 3 to 5 years.

As of September 19, 2025, MeiraGTx Holdings Plc has a mildly bullish trend, supported by positive daily moving averages and KST indicators, despite some bearish signals from the weekly MACD and OBV, while outperforming the S&P 500 year-to-date and over the past year, but underperforming in the 3- and 5-year comparisons.

As of August 25, 2025, MeiraGTx Holdings Plc shows a mildly bullish trend supported by various indicators, having outperformed the S&P 500 year-to-date and over the past year, but underperformed over the longer three and five-year periods.

As of August 7, 2019, MeiraGTx Holdings Plc is considered risky due to its overvaluation and poor financial metrics, including a Price to Book Value of 14.57, negative EV to EBITDA, and significantly low ROCE and ROE, despite a strong year-to-date return of 31.20% compared to the S&P 500's 12.22%.

As of August 7, 2019, MeiraGTx Holdings Plc is considered overvalued and risky due to negative financial metrics, including a high Price to Book Value of 14.57 and poor operational performance reflected in an EV to EBITDA of -3.36, despite a strong 1-year stock return of 43.41%.

As of June 17, 2025, the technical trend is mildly bearish due to daily moving averages indicating a bearish trend, despite some mixed signals from weekly and monthly indicators.

As of March 2022, the management team of MeiraGTx Holdings Plc includes Dr. Keith Harris (Independent Chairman), Dr. Alexandria Forbes (President and CEO), and several Independent Directors: Ms. Ellen Hukkelhoven, Mr. Martin Indyk, Dr. Arnold Levine, Mr. Joel Marcus, and Mr. Neil Mendoza. They are responsible for the company's strategic direction.

MeiraGTx Holdings Plc is a clinical-stage gene therapy company focused on developing treatments for inherited and acquired disorders. As of March 2025, it reported net sales of $2 million and a net loss of $40 million, with a market cap of $508.71 million.